Subscribe now

ARVN’s PDUFA is June 5, 39 days out. Every calendar I’ve seen treats this like a normal oncology binary. It isn’t, and I want to write up why.

Quick orientation on the asset. Vepdegestrant is a PROTAC SERD targeting ER+/HER2- breast cancer. PROTAC means proteolysis-targeting chimera. Instead of blocking the estrogen receptor the way fulvestrant or elacestrant do, it tags the receptor for the cell’s own degradation machinery, and the cell breaks it down. Different mechanism. Oral, once daily. Fulvestrant is a monthly intramuscular injection that nurses hate giving. If vepdegestrant lands with a clean label, the dosing convenience alone is a real commercial argument against the standard of care.

What the scanner is showing

PoA: 81.9%. Indication base rate for breast cancer oncology runs around 85% on Phase 3 to approval per Hay 2014. The drag is that ARVN has never had a drug approved before, and first-time approvers historically run 10-15 percentage points below the indication base rate. The 81.9% reflects that haircut already.

30-day price change: -13.6%. This is actually meaningful in a way most readers will skip past. A chunk of the binary downside has already unwound before the event. That’s the opposite of what burned RCKT longs - RCKT had approval priced in going into the date and dropped 20% on the actual news. ARVN at -13.6% over 30 days has expectations getting dragged down, not up.

Market cap: $674M. Small enough that approval matters, large enough that it’s not a microcap lottery ticket.

TAM/Cap: 8.9x. The second-line ER+/HER2- market is real money. If vepdegestrant captures even modest share against fulvestrant on convenience alone, the runway exists.

STN Risk: 66/100. High. Two amplifiers driving it - first-time approver penalty (+8) and Friday PM PDUFA timing (+5). Two de-riskers pulling back - first-in-class novelty has actual surprise value if approved (-8), high innovation score pulls STN down (-12). Net is still elevated. June 5 is a Friday, and Friday PM PDUFA decisions historically get less day-of price action because nobody wants to hold biotech over a weekend on fresh news.

Innovation: 82/100. First PROTAC degrader to reach FDA approval if it lands. There is no precedent for a degrader getting through.

Dilution Risk: 0/100. No active ATM, no shelf. This is the part that surprised me most. Most small biotechs file paper before a binary as insurance, and ARVN hasn’t.

Insider signal: bearish. Zero net buys over 90 days. I read this two ways and don’t know which is right. Could be a standard pre-PDUFA blackout. Could be lack of conviction.

The thing the calendars are missing

The FDA has no precedent for approving a PROTAC. Reviewers have looked at small molecules, biologics, cell therapies, gene therapies, antibody-drug conjugates. Targeted protein degraders are a different beast, and the CMC review profile is genuinely novel territory.

This is not a clinical risk. STRIVE-ON-equivalent data on vepdegestrant has read out and isn’t the issue. The risk is regulatory-novelty risk, which PoA models trained on traditional small-molecule oncology don’t capture cleanly. My 81.9% number includes the first-time-approver haircut. It does not include a separate haircut for the agency reviewing a mechanism class they’ve never approved before, because there’s no historical base rate to anchor that haircut to. Honest gap in the model. I’d rather flag it than pretend it isn’t there.

The commercialization wrinkle

This came up in a Reddit comment on the same writeup over there, and it’s material enough that it belongs in the body. ARVN and Pfizer are not commercializing vepdegestrant themselves. They’re looking for a third party to take it to market, per ARVN’s own update on the Pfizer collaboration earlier this year. Roughly five weeks from PDUFA, no partner has been announced.

That changes the post-approval setup meaningfully. A clean approval without a commercialization partner means ARVN has the asset but no launch infrastructure on day one, and the partner negotiation now happens with an approved drug instead of an asset-in-development. Whether that’s bullish (more leverage) or bearish (signals difficulty finding a partner at the price they want) depends on what you think about why no partner has signed yet.

Bear cases I want to flag honestly

This is not a one-sided setup.

The first-time-approver penalty is real even though PoA reflects it. ARVN has no commercial sales force. Even on approval, launch execution is a question, and absent a commercialization partner the question gets sharper, not softer.

Friday PM PDUFA dates correlate statistically with weekend-digestion volatility. That’s why STN carries a +5 penalty for Friday PM. Don’t size as if it’s a Tuesday morning decision.

Competing programs are not far behind. ARV-471 is the Pfizer-licensed version of this same compound under a different commercial structure. At least three other oral SERDs (camizestrant, giredestrant) are in late-stage development. First doesn’t mean exclusive for long.

Bearish insider signal. Ninety days of zero net buys before a binary catalyst that the people closest to the asset should have conviction in is not nothing. Could be blackout. Could be conviction.

Where I land

PoA 81.9%, STN 66, Net Edge moderate. This is not an ELITE setup on the scanner. The clinical thesis is strong and the dilution structure is clean. The regulatory novelty and the missing commercialization partner are the two things keeping it from being a clean STRONG. June 5 resolves it either way and I’ll post the postmortem after the FDA decides.

If anyone has pulled recent Form 4 history on ARVN, or knows how the FDA is reviewing PROTAC CMC packages in practice, reply or email back. Both go into the next version of the model.

Full breakdown with the live scanner output and the SEC filing layer is at submarinecatalyst.com.

Not investment advice. Quantitative classifications from public data. I trade my own book off these signals.